Myopia
Conditions
Interventions
Control group: Essilor Stellest control lenses:Control group: The lenses utilize the Highly-Aspheric Lenslet Technology (HALT) technology, with 11 concentric rings of 1,021 micro-lenses distributed ac
Trial group: Parallel complementary lenses:Trial group: A parallel complementary design was used for the spectacle lenses, where the clear zone and blurred zone were arranged in a horizontal stripe pa
Sponsors
The Affiliated Eye Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1.Adolescents and children, aged 6 to 12 years; 2.Spherical refractive error of both eyes: -0.75 to -4.50 D (including -0.75 D and -4.50 D); 3. Astigmatism <= -1.50 D; 4.Willing to wear spectacle lenses and able to accept random assignment; 5. Compliant with follow-up examination schedules and cooperative during examinations.
Exclusion criteria
Exclusion criteria: 1. Intraocular Pressure (IOP) > 21 mmHg; 2. Patients with binocular vision abnormalities, manifest strabismus, or intermittent exotropia with a large angle (> 20 prism diopters [?]); 3. Best-corrected Visual Acuity (BCVA) < 4.9 in either eye; 4. Ocular diseases (other than refractive errors) or systemic diseases that affect visual development; 5. A history of ocular or systemic surgery that affects ocular development; 6. Previous wear of defocus lenses, or use of low-concentration atropine eye drops within 6 months; previous wear of orthokeratology (OK) lenses or use of other myopia intervention methods (e.g., red light-related treatment methods); 7. A history of systemic medication use (drugs affecting growth and development, e.g., growth hormone); 8. Current participation in any clinical research trial on myopia control; 9. Other conditions deemed unsuitable for trial participation by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Axial length;Refractive errors; | — |
Secondary
| Measure | Time frame |
|---|---|
| Contrast sensitivity;Choroidal thickness and blood flow;Binocular visual function; | — |
Countries
China
Contacts
Public ContactYu Lihua
The Affiliated Eye Hospital of Wenzhou Medical University
Outcome results
None listed